MAY 24, 2019 2:01 PM PDT

Blocking this particular protein could slow prostate cancer

Castration-resistant prostate cancer (CRPC) is a particularly aggressive form of prostate cancer. Although the standard of care treatment, which involves disrupting androgen receptor (AR) signaling, is usually effective for 2-3 years, the treatment is not effective long-term and CRPC often develops into lethal metastases.

This is exactly why new research published in Molecular Cancer Research from scientists at Boston University School of Medicine (BUSM) is so exciting. Led by Gerald V. Denis PhD, the BUSM team has determined that blocking a particular protein could prevent the CRPC growth.

"Our findings are significant because current therapeutic options for CRPC are limited and focus primarily on suppressing prostate tumor cells that rely on AR signaling," explained first author Jordan Shafran. "Therefore, it is imperative to identify 'druggable' targets that regulate prostate cancer cell migration and invasion in cells that are either reliant on, or independent of, androgen receptor signaling," he added.

The group of proteins that the researchers investigated is called BET bromodomain proteins and consists of BRD2, BRD3 and BRD4, which regulate gene expression. Following the study’s results, inhibiting the protein BRD4 consistently regulated prostate cancer cell migration and invasion. The same was not found for the proteins BRD2 or BRD3.

The authors elaborate, writing, “We found that BRD4 regulates cell migration across all models of CRPC, regardless of aggressiveness and AR status, whereas BRD2 and BRD3 only regulate migration and invasion in less aggressive models that retain AR expression or signaling. BRD4, a co-regulator of gene transcription, controls migration and invasion through transcription of AHNAK, a large scaffolding protein linked to [the] promotion of metastasis in a diverse set of cancers. Furthermore, treatment of CRPC cell lines with low doses of MZ1, a small-molecule, BRD4-selective degrader, inhibits metastatic potential.”

CRPC is a particularly aggressive form of cancer. Photo: Pixabay

This discovery could have significant implications for the future of CRPC treatments and could offer a new targetable pathway to treat metastatic CRPC, according to the authors.

Sources: Science Daily, Molecular Cancer Research

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JAN 15, 2020
Cell & Molecular Biology
JAN 15, 2020
Cell Division Research Reveals More About a Protein That's Elevated in Cancer
Cell division is a carefully regulated process, cancer is the result when it gets out of control....
JAN 22, 2020
Cancer
JAN 22, 2020
How the VISTA molecule affects immune responses
A new study describes how a molecule named VISTA has been impeding immune responses in cancer therapies. By turning this molecule “off,” resear...
FEB 04, 2020
Health & Medicine
FEB 04, 2020
World Health Organization Outlines Strategy to Eradicate Cervical Cancer
Today—World Cancer Day—the World Health Organization (WHO) announced a draft of a global strategy to eliminate cervical cancer as a public heal...
FEB 18, 2020
Cancer
FEB 18, 2020
Are you at risk of endometrial cancer?
Are you concerned about endometrial cancer? New research published recently in the Journal of Medical Genetics has identified 24 genetic variants that...
FEB 21, 2020
Cancer
FEB 21, 2020
Understanding cancer heterogeneity
A team of researchers from Cornell has taken an innovative approach to crack the diversity code of cancer cells. Using a statistical modeling technique mor...
MAR 15, 2020
Cancer
MAR 15, 2020
The racism behind cancer
Researchers from the University of Colorado Cancer Center have made strides in understanding the reasons behind disparities in outcomes for cancer patients...
Loading Comments...